18 research outputs found
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial
No full textHigh dose Paclitaxel with Granulocyte Colony-stimulating factor in patients with advanced breast cancer Refractory to Anthracycline Therapy: A European Cancer Centre Trial
No full textPharmacokinetics of Paclitaxel and Metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
No full textPharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial
No full text
Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: a European Cancer Centre (ECC) trial
No full textEvaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring
No full textFinal results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity
Full text linkPharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: a European Cancer Centre (ECC) trial
No full textPlasma and Tissue Pharmacokinetics of Epirubicin and Paclitaxel in Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Primary Breast Cancer
No full text
